Clinical Assessment of Hepatic De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2016 Sep 19

PMID 27640119

Citations 38

Authors

Sabina Paglialunga

Clayton A Dehn

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is heralded as the next big global epidemic. Hepatic de novo lipogenesis (DNL), the synthesis of new fatty acids from non-lipid sources, is thought to play a pivotal role in the development of NAFLD. While there is currently no NAFLD-specific therapeutic agent available, pharmaceutical drugs aimed at reducing hepatic fat accretion may prove to be a powerful ally in the treatment and management of this disease. With a focus on NAFLD, the present review summarizes current techniques examining DNL from a clinical perspective, and describes the merits and limitations of three commonly used assays; stable-label isotope tracer studies, fatty acid indexes and indirect calorimetry as non-invasive measures of hepatic DNL. Finally, the application of DNL assessments in the pharmacological and nutraceutical treatment of NAFLD/NASH is summarized. In a clinical research setting, measures of DNL are an important marker in the development of anti-NAFLD treatments.

Citing Articles

Probiotic Supplementation Alleviates Corticosterone-Induced Fatty Liver Disease by Regulating Hepatic Lipogenesis and Increasing Gut Microbiota Diversity in Broilers.

Feng Y, Mei W, Chen Q, Chen X, Ni Y, Lei M Microorganisms. 2025; 13(1).

PMID: 39858968 PMC: 11767375. DOI: 10.3390/microorganisms13010200.

Plasma Lipids Profile in the Prediction of Non-Alcoholic Steatohepatitis in Adults: A Case-Control Study.

Kalopitas G, Mouskeftara T, Liapikos T, Arvanitakis K, Ioannidis A, Malandris K Int J Mol Sci. 2023; 24(16).

PMID: 37628898 PMC: 10454013. DOI: 10.3390/ijms241612717.

Nonalcoholic Fatty Liver Disease Incidence and Remission and Their Predictors During 7 Years of Follow-up Among Finns.

Korpimaki S, Rovio S, Juonala M, Hutri-Kahonen N, Lehtimaki T, Laitinen T J Clin Endocrinol Metab. 2023; 109(1):e291-e305.

PMID: 37463486 PMC: 10735312. DOI: 10.1210/clinem/dgad418.

Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis.

Magee N, Ahamed F, Eppler N, Jones E, Ghosh P, He L Liver Res. 2023; 6(4):238-250.

PMID: 36864891 PMC: 9977163. DOI: 10.1016/j.livres.2022.11.001.

Liver saturated fat content associates with hepatic DNA methylation in obese individuals.

Sehgal R, Perfilyev A, Mannisto V, Agren J, Nilsson E, Kakela P Clin Epigenetics. 2023; 15(1):21.

PMID: 36765383 PMC: 9921201. DOI: 10.1186/s13148-023-01431-x.

References

McGarry J, Foster D . Hormonal control of ketogenesis. Biochemical considerations. Arch Intern Med. 1977; 137(4):495-501. View

Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N . De novo lipogenesis in health and disease. Metabolism. 2014; 63(7):895-902. DOI: 10.1016/j.metabol.2014.04.003. View

Beysen C, Murphy E, Deines K, Chan M, Tsang E, Glass A . Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2011; 55(2):432-42. DOI: 10.1007/s00125-011-2382-3. View

Parks E, Krauss R, CHRISTIANSEN M, Neese R, Hellerstein M . Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Invest. 1999; 104(8):1087-96. PMC: 408572. DOI: 10.1172/JCI6572. View

Softic S, Cohen D, Kahn C . Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci. 2016; 61(5):1282-93. PMC: 4838515. DOI: 10.1007/s10620-016-4054-0. View

Donnelly K, Smith C, Schwarzenberg S, Jessurun J, Boldt M, Parks E . Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115(5):1343-51. PMC: 1087172. DOI: 10.1172/JCI23621. View

Konrad S, Cook S, Goh Y, French M, Clandinin M . Use of deuterium oxide to measure de novo fatty acid synthesis in normal subjects consuming different dietary fatty acid composition1. Biochim Biophys Acta. 1998; 1393(1):143-52. DOI: 10.1016/s0005-2760(98)00061-7. View

Griffith D, Kung D, Esler W, Amor P, Bagley S, Beysen C . Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem. 2014; 57(24):10512-26. PMC: 4281100. DOI: 10.1021/jm5016022. View

Lee W, Bassilian S, Ajie H, Schoeller D, Edmond J, Bergner E . In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. Am J Physiol. 1994; 266(5 Pt 1):E699-708. DOI: 10.1152/ajpendo.1994.266.5.E699. View

10.

Schwarz J, Linfoot P, Dare D, Aghajanian K . Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr. 2002; 77(1):43-50. DOI: 10.1093/ajcn/77.1.43. View

11.

Rabol R, Petersen K, Dufour S, Flannery C, Shulman G . Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A. 2011; 108(33):13705-9. PMC: 3158147. DOI: 10.1073/pnas.1110105108. View

12.

Cusi K . Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012; 142(4):711-725.e6. DOI: 10.1053/j.gastro.2012.02.003. View

13.

Hellerstein M, Kletke C, Kaempfer S, Wu K, Shackleton C . Use of mass isotopomer distributions in secreted lipids to sample lipogenic acetyl-CoA pool in vivo in humans. Am J Physiol. 1991; 261(4 Pt 1):E479-86. DOI: 10.1152/ajpendo.1991.261.4.E479. View

14.

Jacobs S, Jager S, Jansen E, Peter A, Stefan N, Boeing H . Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study. PLoS One. 2015; 10(5):e0127368. PMC: 4435749. DOI: 10.1371/journal.pone.0127368. View

15.

Siler S, Neese R, Hellerstein M . De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am J Clin Nutr. 1999; 70(5):928-36. DOI: 10.1093/ajcn/70.5.928. View

16.

Brandt T . Positional and positioning vertigo and nystagmus. J Neurol Sci. 1990; 95(1):3-28. DOI: 10.1016/0022-510x(90)90113-2. View

17.

Brownsey R, Boone A, Elliott J, Kulpa J, Lee W . Regulation of acetyl-CoA carboxylase. Biochem Soc Trans. 2006; 34(Pt 2):223-7. DOI: 10.1042/BST20060223. View

18.

Lewis J, Ferrara A, Peng T, Hedderson M, Bilker W, Quesenberry Jr C . Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34(4):916-22. PMC: 3064051. DOI: 10.2337/dc10-1068. View

19.

Arunima S, Rajamohan T . Influence of virgin coconut oil-enriched diet on the transcriptional regulation of fatty acid synthesis and oxidation in rats - a comparative study. Br J Nutr. 2014; 111(10):1782-90. DOI: 10.1017/S000711451400004X. View

20.

Geelen M . Medium-chain fatty acids as short-term regulators of hepatic lipogenesis. Biochem J. 1994; 302 ( Pt 1):141-6. PMC: 1137201. DOI: 10.1042/bj3020141. View